$20.23+0.02 (+0.10%)
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States.
PTN in the Healthcare sector is trading at $20.23. The stock is currently 35% below its 52-week high of $31.00, remaining 37.6% above its 200-day moving average. Technical signals show neutral RSI of 57 and bearish MACD signal, explaining why PTN maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonis...
Moby summary of Palatin Technologies, Inc.'s Q2 2026 earnings call
Despite a significant net loss, Palatin Technologies Inc (PTN) strengthens its financial position with a successful public offering and advances in its obesity treatment pipeline.
Palatin Technologies Inc (PTNT) reports significant progress in clinical trials and cost reductions, despite facing financial hurdles and stock delisting issues.
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Galmed Pharmaceuticals (GLMD), 353% surge in interest Protagenic Therapeutics (PTIX), 345% surge in interest Hepion Pharmaceuticals (HEPA), 310% surge in interest Rigel Pharmaceuticals (RIGL), 290% surge in interest Bolt Biotherapeutics (BOLT), 274% surge in interest Palatin Technologies (PTN), 274% surge in interest Krystal Biotech (KRYS), 240% surge in